Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
10/2002
10/09/2002CN1373126A Crystallization formed N-(4-trifluoromethylphenyl)-5-methyl isooxazo-4-carboxamide
10/09/2002CN1372973A Powder snuff of insulin for administration of lung and its preparing process
10/09/2002CN1372966A Capsule 'Pingzhi'
10/09/2002CN1372965A Garlic extract capsule and its preparing process
10/09/2002CN1372957A Medicine for treating diabetes and its preparing process
10/09/2002CN1372955A Oral liquid 'Gubao' and its preparing process
10/09/2002CN1372942A Composition for losing weight of mammal
10/09/2002CN1372938A Composite vitamine and trace-element nutrient for gravida and puerpera
10/09/2002CN1372922A Multilayer emulsion for stabilization of effective component on dermatology and externally used preparation using it
10/09/2002CN1372804A 'Difu' hypoglycemic tea and its preparing process
10/09/2002CN1092053C Process for preparing active aloe powder
10/08/2002WO2001080874A1 Bone-strengthening agents, food compositions for strengthening bone and feed compositions for strengthening bone
10/08/2002US6462169 Amorphous polymeric polyaxial initiators and compliant crystalline copolymers therefrom
10/08/2002US6462078 Antiinflammatory agents; library of plant extracts
10/08/2002US6462060 Heterocyclic-hydroxyimino-fluorene nuclei compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
10/08/2002US6462057 Compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
10/08/2002US6462048 3-(2-(4-methylpiperazin-1-yl)-benzylidene)-1,3-dihydro-indol-2-one for example; useful as psychotherapeutic agents
10/08/2002US6462035 Binding to neuronal nicotinic acetylcholine specific receptor; modulating cholinergic function; reducing nicotine addiction; inflammatory and irritable bowel syndrome, spastic dystonia, chronic and acute pain, eating disorders
10/08/2002US6461647 Method of preparing red ginseng extract
10/08/2002CA2252982C Substituted indazole derivatives and their use as inhibitors phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
10/08/2002CA2196769C Benzimidazole derivatives having dopaminergic activity
10/06/2002CA2378565A1 Crystal structure
10/03/2002WO2002077251A1 Method of recovering pinitol or chiro-inositol in high yield from soy fractions
10/03/2002WO2002077217A2 Human dual specificity protein phosphatase 7-like protein
10/03/2002WO2002077028A1 Polypeptides and nucleic acids for bolekine
10/03/2002WO2002077024A1 Shellfish protein
10/03/2002WO2002077017A2 Medical uses of intercellular communication facilitating compounds
10/03/2002WO2002077003A1 Process for obtaining lignan, pharmaceutical compositions and uses thereof
10/03/2002WO2002076995A2 2-amino-propanol derivatives
10/03/2002WO2002076986A1 Pyrazolopyrimidines as therapeutic agents
10/03/2002WO2002076981A1 Isoquinuclidine derivative, process for producing the same, and medicinal composition containing the same
10/03/2002WO2002076979A1 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
10/03/2002WO2002076973A1 N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient
10/03/2002WO2002076964A1 Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same
10/03/2002WO2002076963A1 Bicyclic guanidine derivatives and therapeutic uses thereof
10/03/2002WO2002076959A1 Five-membered heterocyclic alkanoic acid derivative
10/03/2002WO2002076957A1 Activator for peroxisome proliferator-activated receptor
10/03/2002WO2002076949A1 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
10/03/2002WO2002076948A1 Novel piperidine derivatives as modulators of chemokine receptors
10/03/2002WO2002076947A1 Mch antagonists and their use in the treatment of obesity
10/03/2002WO2002076931A1 Creatine salt having enhanced nutritional and therapeutic efficacy and compositions containing same
10/03/2002WO2002076929A1 Aryl and biaryl compounds having mch modulatory activity
10/03/2002WO2002076925A2 Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
10/03/2002WO2002076507A2 Uses of opg ligand to modulate immune responses
10/03/2002WO2002076503A1 Treatment of central nervous system diseases by antibodies against glatiramer acetate
10/03/2002WO2002076495A1 Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability
10/03/2002WO2002076465A1 Oestrogen and fatty acid monoester as a hypolipidaemic and antidiabetic agent
10/03/2002WO2002076462A1 Drugs for improving insulin resistance
10/03/2002WO2002076455A1 Autonomic controlling agents and health drinks and foods
10/03/2002WO2002076450A1 Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
10/03/2002WO2002076443A1 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases
10/03/2002WO2002076442A1 Stable aqueous liquid preparation
10/03/2002WO2002076435A2 Lipid profile modulation with steroids
10/03/2002WO2002076404A2 Fatty alcohol drug conjugates
10/03/2002WO2002076402A2 Fatty amine drug conjugates
10/03/2002WO2002076400A2 Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
10/03/2002WO2002076381A2 Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
10/03/2002WO2002076376A2 A stable pharmaceutical composition of pravastatin
10/03/2002WO2002076242A1 Nutritional supplement to treat macular degeneration
10/03/2002WO2002076196A1 Transgenic animals expressing antibodies specific for genes of interest and uses thereof
10/03/2002WO2002068687A8 Function and application of tob gene in central nervous system of mammal
10/03/2002WO2002062297A3 Methods and compositions for modulating gluconeogenesis using pgc-1
10/03/2002WO2002059127A3 Pyrazinoquinoxaline derivatives as serotonin agonists and antagonists
10/03/2002WO2002022677A3 Variants of allergenic proteins of the group 2 of dermatophagoides
10/03/2002WO2002010195A3 Modified peptides with increased potency
10/03/2002WO2001098355A3 Cgi-69 compositions and methods of use
10/03/2002WO2001094627A3 Assay techniques based on growth stage dependent expression in c. elegans
10/03/2002WO2001093836A3 Encapsulation of polynucleotides and drugs into targeted liposomes
10/03/2002WO2001071004A3 Proteases
10/03/2002WO2001021812A9 Phosphatases which activate map kinase pathways
10/03/2002US20020143162 Methods
10/03/2002US20020143145 Detcting moduators of binding activity of preferential membrane proteins; obtain animal, incubate with modulator, monitor adjustment in activity from recptors
10/03/2002US20020143141 Cyclic peptide for use in the treatment of eating disorders
10/03/2002US20020143043 For therapy and prophylaxis of rheumatoid arthritis, or of allergic disorders, asthma, inflammation; inhibitors of the adhesion and migration of leucocytes and/or antagonists of adhesion receptor VLA-4 belonging to the integrins group
10/03/2002US20020143036 Pentafluorobenzenesulfonamides and analogs
10/03/2002US20020143020 Novel piperazine derivatives
10/03/2002US20020143017 Pyridazinone aldose reductase inhibitors
10/03/2002US20020143015 Use of vardenafil or pharmaceutically or veterinarily acceptable salt, or solvate in preparation of a medicament for curative, palliative or prophylactic therapy of type 2 diabetes mellitus
10/03/2002US20020143014 Aryl and heteroaryl substituted tetrahydroisoquinolines and use thereof
10/03/2002US20020143008 CRF receptor antagonists and methods relating thereto
10/03/2002US20020143004 Allosteric adenosine receptor modulators
10/03/2002US20020142985 Therapeutic compositions and methods of treating glycolipid storage related disorders
10/03/2002US20020142983 MUC-1 antagonists and methods of treating immune disorders
10/03/2002US20020142456 Protein for use in the treatment of body weight defects
10/03/2002US20020142432 Human endosulfine gene
10/03/2002US20020142054 Laxative; anticholesterol agents
10/03/2002US20020142045 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
10/03/2002US20020142025 Mixture of proteins, carbohydrates, methionine, cysteine, folic acid, pyridoxal and zinc
10/03/2002US20020142004 Immunoreactive and immunotherapeutic molecules
10/03/2002US20020141991 Methods of treating inflammatory disease using antibodies which bind GPR-9-6
10/03/2002US20020141985 Dietetics, eating disorders, antidiabetic agents
10/03/2002US20020141946 Formulation of dipalmitoylphosphatidyl choline (DPPC), insulin and sodium citrate
10/03/2002CA2442325A1 Shellfish protein
10/03/2002CA2442280A1 A stable pharmaceutical composition of pravastatin
10/03/2002CA2442178A1 2-amino-propanol derivatives
10/03/2002CA2441890A1 Oestrogen and fatty acid monoester as a hypolipidaemic and antidiabetic agent
10/03/2002CA2441838A1 Isoquinuclidine derivatives, method of manufacturing the same and therapeutic agents containing these compounds
10/03/2002CA2441806A1 Inosine compounds and their use for treating or preventing an inflammation or a reperfusion disease
10/03/2002CA2441790A1 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
10/03/2002CA2441700A1 Polypeptides and nucleic acids for bolekine
1 ... 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 ... 1298